Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on AbbVie (NYSE:ABBV) and maintains a $200 price target.
July 26, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on AbbVie and maintained a $200 price target, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a $200 price target by a reputable analyst suggests positive sentiment and confidence in AbbVie's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100